Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Charles River Laboratories International, Inc. and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, announced an agreement to manufacture starting ...
read more
Wednesday, February 21, 2024
Charles River Laboratories International, Inc. announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, ...
read more
Monday, December 18, 2023
Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]). CASGEVY is approved in some countries for certain eligible patients.
read more
Wednesday, January 19, 2022
Charles River Laboratories International, Inc. and Valo Health, LLC announced the formation of a multiyear strategic partnership. This agreement will combine Valo’s Opal Computational Platform with Charles River’s drug discovery and development ...
read more
Partnership will provide access to Valence’s machine learning platform to accelerate preclinical drug discovery efforts.
read more
Wednesday, January 18, 2023
Charles River Laboratories International, Inc and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced a viral vector contract development and manufacturing organization...
read more
Friday, September 15, 2023
Charles River Laboratories International, Inc. and Related Sciences, a data science-driven drug discovery firm, announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.
read more
Friday, February 17, 2023
Charles River Laboratories International and Purespring Therapeutics, a gene therapy company dedicated to transforming the treatment of kidney diseases, have announced a plasmid DNA contract development and manufacturing organization (CDMO) ...
read more
Charles River Laboratories International, Inc. and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and ...
read more
Charles River Laboratories International, Inc. announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and ...
read more
Friday, February 17, 2023
Charles River Laboratories International, Inc. announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines access to Logica™.
read more
Charles River Laboratories International, Inc. and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, announced a plasmid DNA and retrovirus vector production program agreement.
read more
Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions.
read more
Charles River Laboratories International, Inc. and ASC Therapeutics announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A.
read more
Wednesday, November 15, 2023
Charles River Laboratories International, Inc. and Aitia, a pioneer in Causal AI and Digital Twins, have entered into a strategic agreement, granting Aitia access to Logica™—Charles River's Artificial Intelligence (AI)-powered drug solution platform....
read more